A new real estate Ponzi scheme named EMAAR has duped over 4,000 Nigerian investors, using fintech accounts to lure victims ...

Beijing’s latest show of force came in the form of its Liaoning carrier strike group launching aircraft near Okinawa ...

Volodymyr Zelenskyy says work on 20- point plan to end war being finalized Ukrainian leader expecting to deliver document to ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting (SUO) ...

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly ...

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first ...

Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high ...

Enhertu (trastuzumab Deruxtecan [T-DXd]) treated patients continue to be eligible for enrollment in FLAMINGO-01. The Company believes that GLSI-100 will synergize with any trastuzumab based treatment ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg ...

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune ...

Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology  Oslo, Norway, 8 December 2025 - Oncoinvent, a clinical stage, radiopharmaceutical ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...